Nail onychomycosis or fungus infection is caused by a fungus called Trichophyton rubrum and Trichophyton mentagrophytes. However, few cases may also be caused by yeasts and molds. Fungi grow and spread due to conditions of warmth and moisture. The infection begins as a white or yellow spot under the tip of the nail and as it spreads deeper into the nail, it causes potentially painful nail discoloration, thickening, and development of crumbling edges. Onychomycosis commonly affects toenails than in fingernails, as toenails are often confined in a dark, warm, moist environment inside shoes where fungi can thrive. Old age people are more likely to be affected by the disease due to suppressed nail growth and immunity, and other complications.
Increasing geriatric population across the globe is another major factor driving growth of the market. According to the Population Prospects report by the United Nations, the number of people aged 60 years and above would reach 1.3 billion by 2025.
Key features of the study:
- This report provides in-depth analysis of dermatophytic onychomycosis treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2018 – 2026), considering 2017, as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players It profiles leading players in the global dermatophytic onychomycosis treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans Key companies covered as a part of this study include Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc, GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc., Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and Merz Pharma Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics The global dermatophytic onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the dermatophytic onychomycosis treatment market